Japan’s Takeda Sees Largest Earnings Gain In Six-Plus Years
This article was originally published in PharmAsia News
Takeda Pharmaceutical registered its biggest stock market gain in six years after an analyst noted the Japanese firm was experiencing steady earnings. The Nikko Citigroup analyst also noted, however, that Takeda still does not have a successor for its Actos (pioglitazone hydrochloride) diabetes drug, whose patent is set to expire in 2011. He said Takeda is looking to its SYR-322 (alogliptin) type 2 diabetes drug and a joint-venture stomach ulcer drug to counter the expected decline in Actos sales, and has ample cash for mergers and acquisitions. (Click here for more
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.